Results Presented at the ADA 69th Scientific Sessions Demonstrate that INCB13739, Incyte's Oral 11beta-HSD1 Inhibitor, Significantly Improves Glycemic Control, Insulin Sensitivity and Total Cholesterol in Patients with Type 2 Diabetes

Click here to view press release

Incyte Provides Update on Special Protocol Assessment for INCB18424 as a New Treatment for Myelofibrosis; Announces Plan to Initiate a Phase III Registration Trial in Europe in June

Click here to view press release

To view or listen to our most recent corporate presentations, please use the link provided below

Click here for recent conferences and presentations

Product Pipeline - Learn more about our drug discovery programs.

Incyte's Clinical Trials
To learn more about Incyte's ongoing clinical trials, please go to the following links:

INCB18424: Polycythemia vera/Essential Thrombocythemia http://www.clinicaltrials.gov/ct2/show/NCT00726232

INCB18424: Topical psoriasis http:://www.clinicaltrials.gov/ct2/show/NCT00617994